Home > Press > UCSB Among Team Awarded $12.5 Million
Abstract:
Chosen by NIH as a Program of Excellence in Nanotechnology
A partnership of scientists from the College of Engineering at UC Santa Barbara, Washington University in St. Louis and UC Berkeley have been awarded $12.5 million to develop nanoscale agents to provide early diagnosis and treatment of acute pulmonary and systemic vascular injury over the next five years. The organizations were selected as a collaborative "Program of Excellence in Nanotechnology" (PEN) by the National Heart Lung and Blood Institute of the National Institutes of Health (NIH).
The team, led at UCSB by Professor Craig Hawker, Director of the Materials Research Laboratory, and coordinated by Professor Karen Wooley at Washington University in St. Louis will use nanoscale materials as carriers for diagnostic systems and to deliver therapeutic agents. Hawker and Wooley working with Professor Jean Frechet, PhD, at the University of California, Berkeley, will be developing a way to trigger a breakdown of the nanoparticles after a payload, such as a drug or antiviral agent, is delivered directly to a diseased zone. Targeted nanoparticles will search out arteries that are under stress or are diseased.
The nanoscale designs are based on the concept that advanced nanotechnologies can help overcome inherent limitations of molecular imaging and therapeutic gene transfer.
"I think part of the reason we received this grant was due to UCSB's excellence in soft materials and in engineering," said Hawker. Acute vascular injury and inflammation have been chosen as general targets since they affect tissues broadly, including those of the lung and cardiovascular system.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over 14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||